Eshel Hayarden: Series B Collateral Headroom Depends Too Much on KAVA
Series B is compliant with its collateral covenant, but 133.37% coverage against a 130% requirement leaves only about NIS 1.7 million of headroom. As long as KAVA is only partly sold and surplus cash still has to pass through project finance and Diurim, bond comfort is weaker than the Mavo'ot Dromim progress headline suggests.
The first quarter improved Eshel Hayarden's execution story: Mavo'ot Dromim secured project finance and signed binding sales after the balance-sheet date, but Series B shows a less comfortable debt layer. This bond is not mainly supported by Mavo'ot Dromim. Its security package relies primarily on rights to receive 50% of KAVA surplus through Diurim and on the trust account that is supposed to receive those surplus amounts. The collateral-to-debt ratio is 133.37% versus a 130% requirement, so there is no breach, but the numerical headroom is narrow. In shekel terms, pledged KAVA surplus is only about NIS 1.7 million above the required threshold. KAVA itself is still 23% marketed, with 62 contracts out of 246 housing units and no new contracts after the balance-sheet date through the report publication date. Diurim was profitable in the quarter, and Eshel Hayarden's share of that profit was NIS 545 thousand, but there was no cash distribution from equity-accounted companies. The current read is therefore clear: Series B meets the requirement, but bond comfort depends too heavily on faster KAVA execution and on surplus cash that remains controlled by the project-finance structure.
The Ratio Is Compliant, but the Cushion Is Tiny
Series B is an unrated, unlinked bond with a fixed 7.03% coupon. Principal amortization begins on December 31, 2026 and continues in five installments through the end of 2028. As of March 31, 2026, principal outstanding was NIS 49.9 million, and the book fair value including accrued interest was NIS 50.7 million.
The core collateral is a pledge over Diurim's rights to receive 50% of KAVA surplus, plus a pledge over the company's rights in the trust account into which those surplus amounts are supposed to flow. That structure is normal in residential development: the project is financed and controlled by the lender, surplus is released only after project-finance conditions are met, and bondholders receive rights over the surplus layer, not free cash already sitting at the issuer. The uncomfortable part is not the structure itself. It is the short distance from the covenant floor.
| Series B item | Number | Why it matters |
|---|---|---|
| Book fair value including accrued interest | NIS 50.7m | A close proxy for the economic debt base |
| Pledged KAVA surplus in Appendix A | NIS 67.7m | The asset supporting the collateral ratio |
| Actual collateral-to-debt ratio | 133.37% | Above the requirement, but only slightly |
| Calculated cushion above the 130% threshold | About NIS 1.7m | Sensitive to small changes in surplus or debt |
The last line is the point. A 133.37% ratio looks less tight when expressed as a percentage, but in absolute terms it leaves a very small safety margin above the required level. In that setting, even a small update to expected KAVA surplus, project costs, sales pace, or accrued debt can become a number bondholders need to watch closely.
KAVA Is Moving, but Not Fast Enough for a Comfortable Collateral Read
KAVA is not stalled. It is a 246-unit residential project in Tiberias, with expected project revenue of NIS 581.6 million and signed contracts totaling NIS 131.8 million by the end of March. The issue is pace: only two contracts were signed in the first quarter, and the marketing rate moved from 22% at the end of 2025 to 23% at the end of March 2026. The row for contracts signed after the balance-sheet date through the report date shows no additional increase.
That matters because Series B collateral is not measured against the entire broader KAVA opportunity. It is measured against expected surplus in the pledged project. Appendix A shows 62 units sold, expected gross profit of NIS 48.4 million, equity of NIS 19.3 million, and expected surplus of NIS 67.7 million. Those are the numbers holding the collateral ratio. At the same time, the broader project tables also show the additional KAVA 203-204 phase, with 64 units, expected revenue of NIS 163.7 million, expected profit of NIS 67.8 million, and company-share surplus of NIS 42.5 million. That distinction is important: future project value is not the same as collateral already supporting the bond today.
The conclusion is not that KAVA is weak. The expected margin in the additional phase is high, and the active project already has signed contracts. But Series B needs more than a good-looking project table. It needs sales to advance, costs not to erode surplus, and the lender to release surplus into the pledged route. Until that happens, bond comfort rests on an estimate rather than cash the company can freely use.
Diurim Is Profitable, but Cash Has Not Reached the Bond Layer
Diurim, the company that holds KAVA and is 50% owned by Eshel Hayarden, reported apartment-sale revenue of NIS 12.5 million and net profit of NIS 1.1 million in the quarter. Eshel Hayarden's share of profit was NIS 545 thousand, and the carrying value of its Diurim investment was NIS 19.5 million, including NIS 13.6 million of loans and NIS 5.9 million of profit share.
That is positive, but it still does not change Series B debt comfort. The cash-flow statement did not show dividends or receipts on account of profit distributions from equity-accounted companies in the quarter. In other words, Diurim is already contributing accounting profit, but the value is still passing through an investment and loans to an associate, not through cash entering the issuer or the trust account for bondholders.
This is the difference between project profit and bond security. Diurim's profit can improve the carrying value of the investment, but Series B holders need KAVA to keep selling, expected surplus to hold, and cash to be released by the project-finance mechanism. Until those steps are complete, the collateral ratio has to be tested again every quarter.
The Next Read Depends on Released Surplus, Not Only on Marketing Progress
The current Series B read is cautiously positive: there is no breach, expected surplus exists, and KAVA is already selling apartments. But about NIS 1.7 million of headroom above the collateral threshold is not enough to ignore execution pace. A better read would require a clear increase in KAVA's marketing rate, preservation of expected surplus against the zero report, and the beginning of movement from Diurim profit or loan repayment into cash accessible to the issuer and bondholders.
The counter-thesis is reasonable: if KAVA sales accelerate and the zero report continues to support surplus of about NIS 67.7 million or more, the narrow first-quarter ratio may prove to be a temporary transition point. The evidence is not there yet. Mavo'ot Dromim improved the company's growth story, while Series B reminds investors that debt comfort is measured in a different project, through a different account, and by the moment KAVA stops being expected surplus and becomes released cash.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.